Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Departments

Opioid therapy and sleep apnea (June 2016)

Aaron S. Geller, MD
Cleveland Clinic Journal of Medicine February 2017, 84 (2) 91-94; DOI: https://doi.org/10.3949/ccjm.84c.02001
Aaron S. Geller
Tufts University School of Medicine, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

TO THE EDITOR: I enjoyed Dr. Galicia-Castillo’s article about long-term opioid therapy in older adults,1 which reaffirmed the imperative to “start low and go slow” to minimize the risk of addiction. However, the article missed an opportunity to raise awareness regarding another extremely important side effect of chronic prescription opioid consumption, that of ingestion prior to sleep, with consequent cessation of breathing leading to death.

According to the Drug Enforcement Administration,2 most narcotic deaths are a result of respiratory depression. And the American Pain Society has stated, “No patient has succumbed to [opioid] respiratory depression while awake.”3

Dr. Galicia-Castillo noted that the prevalence of central sleep apnea in chronic opioid users is 24%, based on a review by Correa et al.4 As alarming as this number is, other investigators have estimated it to be even higher—as high as 50% to 90%.5

Walker et al,6 in a study of 60 patients, found that the higher the opioid dose the patients were on, the more episodes of obstructive sleep apnea and central sleep apnea per hour they had. Yet prescribing a low dose does not adequately protect the chronic opioid user. Farney et al7 reported that oxygen saturation dropped precipitously—from 98% to 70%—15 minutes after a patient took just 7.5 mg of hydrocodone in the middle of the night. Mogri et al8 reported that a patient had 91 apnea events within 1 hour of taking 15 mg of oxycodone at 2 am.

Opioids, benzodiazepines, barbiturates, and ethanol individually and additively suppress medullary reflex ventilatory drive during sleep, especially during non–rapid-eye-movement (non-REM) sleep.6 During waking hours, in contrast, there is redundant backup of cerebral cortical drive, ensuring that we keep breathing. Therefore, people are most vulnerable to dying of opioid ingestion during sleep.

Moreover, oxygen desaturation during episodes of sleep apnea may precipitate seizures (which may be lethal) or coronary vasospasm with consequent malignant arrhythmias and myocardial ischemia.

Continuous positive airway pressure protects against obstructive sleep apnea, but not against central sleep apnea.9

Patients need to be aware of the danger, and physicians need to consider the pharmacokinetic profiles of the opioid preparations they prescribe. If patients are taking an opioid that has a short half-life, such as immediate-release oxycodone, they should not take it within 5 hours of sleep. Longer-lasting preparations need a longer interval, and some, such as extended-release tramadol, may need to be taken only on awakening.

Safe sleep can be facilitated by medications that are sedating but do not compromise ventilation. Optimal agents also enhance restorative REM and stage III and IV deep-sleep duration, and some may have the additional benefit of reducing the risk of cancer.10,11 Such agents may include baclofen, cyproheptadine, gabapentin, mirtazepine, and melatonin. Nonpharmacologic measures include sleep hygiene, aerobic exercise, and cognitive behavioral therapy.

A retrospective study12 found that 301 (60.4%) of 498 patients who died while on opioid therapy and whose death was judged to be related to the opioid were also taking benzodiazepines. Patients who take opioids should avoid taking benzodiazepines, barbiturates, or alcohol before going to sleep, and physicians should be extremely cautious about prescribing benzodiazepines and barbiturates to patients who are on opioids.

  • Copyright © 2017 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Galicia-Castillo M
    . Opioids for persistent pain in older adults. Cleve Clin J Med 2016; 83:443–451.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Drug Enforcement Administration
    . Drugs of Abuse. 2005 Edition.Washington, DC: US Government Printing Office, 2005:19.
  3. ↵
    1. American Pain Society
    , Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 4th ed. Glenview, IL: American Pain Society, 1999:30.
  4. ↵
    1. Correa D,
    2. Farney RJ,
    3. Chung F,
    4. Prasad A,
    5. Lam D,
    6. Wong J
    . Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg 2015; 120:1273–1285.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Panagiotou I,
    2. Mystakidou K
    . Non-analgesic effects of opioids: opioids’ effects on sleep (including sleep apnea). Curr Pharm Des 2012; 18:6025–6033.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Walker JM,
    2. Farney RJ,
    3. Rhondeau SM,
    4. et al
    . Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007; 3:455–461. Erratum in J Clin Sleep Med 2007; 3:table of contents.
    OpenUrlPubMed
  7. ↵
    1. Farney RJ,
    2. Walker JM,
    3. Cloward TV,
    4. Rhondeau S
    . Sleep-disordered breathing associated with long-term opioid therapy. Chest 2003; 123:632–639.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Mogri M,
    2. Khan MI,
    3. Grant BJ,
    4. Mador MJ
    . Central sleep apnea induced by acute ingestion of opioids. Chest 2008; 133:1484–1488.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Guilleminault C,
    2. Cao M,
    3. Yue HJ,
    4. Chawla P
    . Obstructive sleep apnea and chronic opioid use. Lung 2010; 188:459–468.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Kao CH,
    2. Sun LM,
    3. Liang JA,
    4. Chang SN,
    5. Sung FC,
    6. Muo CH
    . Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study. Mayo Clin Proc 2012; 87:430–436.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kripke DF
    . Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Res 2016; 5:918.
    OpenUrl
  12. ↵
    1. Gomes T,
    2. Mamdani MM,
    3. Dhalla IA,
    4. Paterson JM,
    5. Juurlink DN
    . Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011; 171:686–691.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 84 (2)
Cleveland Clinic Journal of Medicine
Vol. 84, Issue 2
1 Feb 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Opioid therapy and sleep apnea (June 2016)
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Opioid therapy and sleep apnea (June 2016)
Aaron S. Geller
Cleveland Clinic Journal of Medicine Feb 2017, 84 (2) 91-94; DOI: 10.3949/ccjm.84c.02001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Opioid therapy and sleep apnea (June 2016)
Aaron S. Geller
Cleveland Clinic Journal of Medicine Feb 2017, 84 (2) 91-94; DOI: 10.3949/ccjm.84c.02001
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Departments

  • When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
  • Our Peer-Reviewers for 2023
  • Our Peer-Reviewers For 2022
Show more Departments

Letters to the editor

  • In Reply: In defense of the anion gap
  • In defense of the anion gap
  • In Reply: Classic diabetic ketoacidosis and the euglycemic variant
Show more Letters to the editor

Similar Articles

Subjects

  • Drug Therapy
  • Emergency Medicine
  • Hospice & Palliative Medicine
  • Pain

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire